default author photo

Rigel Suzuki

Hokkaido University - Department of Microbiology and Immunology

SCHOLARLY PAPERS

3

DOWNLOADS

240

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

An Artificial Intelligence Nanopore Platform Detects Omicron SARS-CoV-2 in Clinical Samples

Number of pages: 36 Posted: 23 Nov 2022
Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University - Department of Microbiology and Immunology, Hokkaido University - Department of Molecular Psychoimmunology, Aipore Inc., Hokkaido University - Department of Molecular Psychoimmunology, National Institute for Quantum and Radiological Science and Technology (QST) - Group of Quantum immunology, Hokkaido University - Department of Molecular Psychoimmunology, Aipore Inc., Aipore Inc., The University of Osaka, Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University Hospital - Division of Laboratory and Transfusion Medicine, JCHO (Japan Community Healthcare Organization) - Department of Respiratory Medicine, National Hospital Organization (NHO) - Department of Respiratory Medicine, Hokkaido University - Department of Biostatistics, Hokkaido University - Department of Hematology Medicine, The University of Osaka - The Institute of Scientific and Industrial Research (SANKEN), Hokkaido University - Department of Microbiology and Immunology, Hokkaido University - International Medical Department, The University of Osaka - The Institute of Scientific and Industrial Research (SANKEN) and Hokkaido University - Department of Molecular Psychoimmunology
Downloads 106 (664,543)

Abstract:

Loading...

COVID-19 diagnosis, AI-nanopore, SARS-CoV-2 variants

2.

SARS-CoV-2 Omicron Detection by Antigen Tests Using Saliva

Number of pages: 14 Posted: 18 Apr 2022
Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University, affiliation not provided to SSRN, Hokkaido University - Department of Molecular Psychoimmunology, Hokkaido University - Department of Microbiology and Immunology, Hokkaido University, Hokkaido University, affiliation not provided to SSRN, Hokkaido University - Department of Hematology Medicine, Hokkaido University - Department of Biostatistics, Hokkaido University - Department of Microbiology and Immunology, Hokkaido University - Department of Molecular Psychoimmunology and Hokkaido University - International Medical Department
Downloads 81 (809,932)

Abstract:

Loading...

SARS-CoV-2, COVID-19, Saliva, Lumipulse, ICA, CLEIA

3.

Safety and Immunogenicity of SARS-CoV-2 Self-Amplifying RNA Vaccine Expressing Anchored RBD: A Randomised, Observer-Blind, Phase 1 Study

Number of pages: 139 Posted: 24 Jan 2023
VLP Therapeutics Japan, LLC, VLP Therapeutics Japan, LLC, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, National Hospital Organization (NHO), Nagoya Medical Center, Clinical Research Center, Hokkaido University - Department of Microbiology and Immunology, VLP Therapeutics Japan, LLC, VLP Therapeutics Japan, LLC, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, Hokkaido University - Department of Microbiology and Immunology, VLP Therapeutics, Inc., VLP Therapeutics, Inc., VLP Therapeutics, Inc., VLP Therapeutics, Inc., VLP Therapeutics Japan, LLC, Kitasato University - Department of Research, Hokkaido University - Department of Microbiology and Immunology, National Hospital Organization (NHO), Nagoya Medical Center, Clinical Research Center, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, VLP Therapeutics, Inc. and VLP Therapeutics Japan, LLC
Downloads 53 (1,041,696)

Abstract:

Loading...

SARS-CoV-2, self-amplifying RNA vaccine, phase 1 study